This HTML5 document contains 94 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://www.rxlist.com/cgi/generic3/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00289/identifier/bindingdb/
n2http://linked.opendata.cz/resource/drugbank/drug/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00289/identifier/pubchem-compound/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/mesh/concept/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00289/identifier/kegg-drug/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00289/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00289/identifier/drugbank/
n22http://bio2rdf.org/drugbank:
n27http://linked.opendata.cz/resource/drugbank/drug/DB00289/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n7http://linked.opendata.cz/resource/drugbank/patent/
n29http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00289/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00289/identifier/chebi/
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00289/identifier/pharmgkb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00289/identifier/wikipedia/
n19http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00289
rdf:type
n3:Drug
n3:description
Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]
n3:dosage
n16:271B4B36-363D-11E5-9242-09173F13E4C5 n16:271B4B3B-363D-11E5-9242-09173F13E4C5 n16:271B4B3C-363D-11E5-9242-09173F13E4C5 n16:271B4B3D-363D-11E5-9242-09173F13E4C5 n16:271B4B37-363D-11E5-9242-09173F13E4C5 n16:271B4B38-363D-11E5-9242-09173F13E4C5 n16:271B4B39-363D-11E5-9242-09173F13E4C5 n16:271B4B3A-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J: Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry. 2006 Mar;67(3):415-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16649828 # Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, Adli M: Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report. Pharmacopsychiatry. 2006 Mar;39(2):79-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16555170 # Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH: Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005 Oct;66(10):1234-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16259536 # Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16113620 # McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI: Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007 Mar;68(3):390-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17388708 # Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents] Encephale. 2005 May-Jun;31(3):337-48. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16142049# Simpson D, Plosker GL: Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64(2):205-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14717619 # Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009 Nov;25(11):2745-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19785510 # Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children] Encephale. 2007 Sep;33(4 Pt 1):621-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18033153
n3:group
approved
n3:halfLife
5 hours
n3:indication
For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures.
n3:manufacturer
n8:271B4B2E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n22:DB00289 n29:DB00289
dcterms:title
Atomoxetine
adms:identifier
n15:Atomoxetine n17:PA134688071 n23:127342 n24:49516 n25:50133749 n26:D02574 n27:0002-3227-30 n28:DB00289 n30:46506160 n31:54841
n3:mechanismOfAction
The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined through in-vitro studies. Atomoxetine appears to have minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors.
n3:packager
n8:271B4B2C-363D-11E5-9242-09173F13E4C5 n8:271B4B2D-363D-11E5-9242-09173F13E4C5 n8:271B4B2A-363D-11E5-9242-09173F13E4C5 n8:271B4B2B-363D-11E5-9242-09173F13E4C5 n8:271B4B28-363D-11E5-9242-09173F13E4C5 n8:271B4B29-363D-11E5-9242-09173F13E4C5 n8:271B4B26-363D-11E5-9242-09173F13E4C5 n8:271B4B27-363D-11E5-9242-09173F13E4C5 n8:271B4B25-363D-11E5-9242-09173F13E4C5
n3:patent
n7:5658590 n7:2209735
n3:synonym
Tomoxetina Tomoxetinum Tomoxetine (-)-Tomoxetine
n3:toxicity
The most commonly reported symptoms accompanying acute and chronic overdoses are somnolence, agitation, hyperactivity, abnormal behavior, and gastrointestinal symptoms.
n3:volumeOfDistribution
* 0.85 L/kg
n9:hasAHFSCode
n10:28-92-00
n3:foodInteraction
Take without regard to meals. In the presence of food, the absorption rate is reduced, without the quantity absorbed being affected.
n3:proteinBinding
At therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin.
n3:synthesisReference
Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei, "Processes for the preparation of atomoxetine hydrochloride." U.S. Patent US20060211772, issued September 21, 2006.
n5:hasConcept
n6:M0124112
foaf:page
n12:atomoxetine.html n13:strattera.htm
n3:IUPAC-Name
n4:271B4B42-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4B48-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4B47-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4B44-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4B45-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4B46-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4B40-363D-11E5-9242-09173F13E4C5 n4:271B4B57-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4B41-363D-11E5-9242-09173F13E4C5 n4:271B4B3E-363D-11E5-9242-09173F13E4C5 n4:271B4B58-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4B3F-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n19:N06BA09
n3:H-Bond-Acceptor-Count
n4:271B4B4E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4B4F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4B49-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4B4A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4B4C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4B4B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4B4D-363D-11E5-9242-09173F13E4C5
n3:absorption
Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs. Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) have no effect on atomoxetine bioavailability. Absorption is minimally affected by food.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
82248-59-7
n3:category
n3:clearance
* 0.35 L/hr/kg [after oral administration in adult extensive metabolizers] * 0.03 L/hr/kg [administration of atomoxetine to poor metabolizers]
n3:containedIn
n20:271B4B35-363D-11E5-9242-09173F13E4C5 n20:271B4B33-363D-11E5-9242-09173F13E4C5 n20:271B4B34-363D-11E5-9242-09173F13E4C5 n20:271B4B31-363D-11E5-9242-09173F13E4C5 n20:271B4B32-363D-11E5-9242-09173F13E4C5 n20:271B4B2F-363D-11E5-9242-09173F13E4C5 n20:271B4B30-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4B53-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4B55-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4B56-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4B52-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4B51-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4B54-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4B43-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4B50-363D-11E5-9242-09173F13E4C5